Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early revaccination after chemotherapy for childhood acute lymphoblastic leukemia
NL-OMON33573Phase 3Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Pediacel + Hib, pneumococcal 7-valent conjugate vaccine, Meningococcal group C polysaccharide conjugate vaccine and Pneumo 23 in Vaccine-preventable disease (VPD), sponsored by University Medical Center Utrecht. Primary endpoints: Effect of early revaccination after chemotherapy and Comparison of pneumococcal polysaccharide versus conjugate vaccine responses. Started Jul 2009; status: active, not recruiting.
02
Drugs
Pediacel + Hibpneumococcal 7-valent conjugate vaccineMeningococcal group C polysaccharide conjugate vaccinePneumo 23
03
Conditions
Vaccine-preventable disease (VPD)
Beyond the preview
Go deeper on NL-OMON33573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33573.